NCT01929499

Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer

Efficacy of Adjuvant Immunotherapy With Cytokine-induced Killer Cells in Patients With Stage II/III Colon Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 210 (estimated)
• Sponsor: Yanjuan Zhu · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

It has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. Thus, immunotherapy may decrease the recurrence rate after surgery. CIK cells transfusion has been reported as an effect therapy in advanced cancers. In another retrospective study, investigators found that adjuvant CIK therapy would prolong the disease-free survival (DFS) for colorectal cancer patients. The purpose of this study is to determine wether adjuvant immunotherapy with CIK cells in patients with colon cancer after operation will prolong DFS, and overall survival (OS).

Conditions

• Colonic Neoplasms

Interventions

Type	Name	Description
BIOLOGICAL	cytokine-induced killer cells

Timeline

• Start date: 2013-09-01
• Primary completion: 2016-08-01
• Completion: 2019-08-01
• First posted: 2013-08-28
• Last updated: 2013-08-29

Locations

1 site across 1 country: China